Formula 1A Cationic Lipid Synthesis for Intracellular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nucleic acid therapeutics face challenges in achieving stable formulations with long shelf-life and efficient intracellular delivery, particularly for biologically active molecules such as proteins, polynucleotides, and low molecular weight compounds, due to limited targeting capabilities.
Innovation Solution
Development of novel lipid compositions and methods for synthesizing a compound of formula 1A, involving specific chemical reactions and purifications, to facilitate targeted intracellular delivery of therapeutic molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional delivery methods are used for nucleic acid therapeutics, then the molecules can be administered, but they fail to achieve stable formulations with long shelf-life and efficient intracellular delivery
Solution Approach 1:
The patent employs cationic lipids combined with nucleic acids to form lipoplex complexes. The cationic lipid component provides membrane fusion capabilities and endosomal escape, while the nucleic acid component provides therapeutic function. This composite material approach resolves the contradiction by creating a formulation that is both stable for storage and efficient for intracellular delivery, as the lipid-nucleic acid complex protects the nucleic acid during storage and facilitates targeted delivery to cells.
2Ease of operation
If nucleic acids are delivered in polar aqueous solution, then they remain soluble, but side-reactions occur that compromise stability
Solution Approach 1:
The patent creates a protective environment by forming lipoplex complexes where the lipid bilayer structure shields the nucleic acid from the aqueous environment. This inert-like protective barrier prevents unwanted side-reactions between the nucleic acid and aqueous components while maintaining solubility and bioavailability. The lipid coating acts as a protective atmosphere that preserves formulation stability.
3Stability of the object's composition
If nonpolar solvents are used for nucleic acid encapsulation, then anhydrous conditions are achieved, but side-reactions occur that compromise stability
Solution Approach 1:
The patent modifies the physical and chemical parameters of the formulation by using cationic lipids with specific headgroup compositions and chain lengths. These parameter changes enable the formation of stable lipoplexes that can be prepared in anhydrous conditions without side-reactions. The specific lipid parameters (charge density, hydrophobicity, molecular weight) are optimized to prevent unwanted reactions while maintaining encapsulation efficiency.
4Ease of manufacture
If traditional lipid formulations are used, then manufacturing is simple, but targeted intracellular delivery of biologically active molecules is limited
Solution Approach 1:
The cationic lipid formulations described in the patent are designed to perform multiple functions: they provide structural stability, facilitate cellular uptake, enable endosomal escape, and allow for targeted delivery. The universal cationic lipid platform can be used with various types of biologically active molecules (nucleic acids, proteins, small molecules) while maintaining ease of manufacture. This multi-functionality resolves the contradiction by providing both simplicity and versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel lipid compositions enhance the delivery of biologically active molecules, including nucleic acids, to targeted cells, demonstrating significant knockdown activity and stability.
Implementation Method 1
reacting 8-bromooctanoic acid with methanol in the presence of H2SO4 to produce methyl 8-bromooctanoate
Implementation Method 2
reacting 8-bromooctanoate with benzyl amine to produce dimethyl 8,8′-(benzanediyl)dioctanoate
Implementation Method 3
hydrogenating dimethyl 8,8′-(benzanediyl)dioctanoate to produce dimethyl 8,8′-azanediyldioctanoate
Implementation Method 4
protecting dimethyl 8,8′-azanediyldioctanoate by reacting with di-t-butyl dicarbonate (BOC) anhydride to produce dimethyl 8,8′-(BOC-azanedil) dioctanoate
Implementation Method 5
reacting dimethyl 8,8′-(BOC-azanedil) dioctanoate with sodium hydroxide to produce 8,8′-(BOC-azanediyl) dioctanoic acid
Data Source
AI summary
What is described is a method of synthesis of the compound of formula 1A,or a salt thereof, whereinR3 is a linear or branched alkene of 1, 2, 3, 4, 5 or 6 carbons;R4 and R5 are the same or different, each a hydrogen, or a linear or branched alkyl of 1, 2, 3, 4, 5 or 6 carbons; andL3 is a bond or an alkane of 1, 2, 3, 4, 5 or 6 carbons.